Literature DB >> 22972034

MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

D-J Min1, T Ezponda, M K Kim, C M Will, E Martinez-Garcia, R Popovic, V Basrur, K S Elenitoba-Johnson, J D Licht.   

Abstract

Multiple myeloma (MM) represents the malignant proliferation of terminally differentiated B cells, which, in many cases, is associated with the maintenance of high levels of the oncoprotein c-MYC. Overexpression of the histone methyltransferase MMSET (WHSC1/NSD2), due to t(4;14) chromosomal translocation, promotes the proliferation of MM cells along with global changes in chromatin; nevertheless, the precise mechanisms by which MMSET stimulates neoplasia remain incompletely understood. We found that MMSET enhances the proliferation of MM cells by stimulating the expression of c-MYC at the post-transcriptional level. A microRNA (miRNA) profiling experiment in t(4;14) MM cells identified miR-126* as an MMSET-regulated miRNA predicted to target c-MYC mRNA. We show that miR-126* specifically targets the 3'-untranslated region (3'-UTR) of c-MYC, inhibiting its translation and leading to decreased c-MYC protein levels. Moreover, the expression of this miRNA was sufficient to decrease the proliferation rate of t(4;14) MM cells. Chromatin immunoprecipitation analysis showed that MMSET binds to the miR-126* promoter along with the KAP1 corepressor and histone deacetylases, and is associated with heterochromatic modifications, characterized by increased trimethylation of H3K9 and decreased H3 acetylation, leading to miR-126* repression. Collectively, this study shows a novel mechanism that leads to increased c-MYC levels and enhanced proliferation of t(4;14) MM, and potentially other cancers with high MMSET expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972034      PMCID: PMC3886861          DOI: 10.1038/leu.2012.269

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  54 in total

1.  Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

Authors:  N C Gutiérrez; M E Sarasquete; I Misiewicz-Krzeminska; M Delgado; J De Las Rivas; F V Ticona; E Fermiñán; P Martín-Jiménez; C Chillón; A Risueño; J M Hernández; R García-Sanz; M González; J F San Miguel
Journal:  Leukemia       Date:  2010-01-07       Impact factor: 11.528

2.  Production and titration of lentiviral vectors.

Authors:  Patrick Salmon; Didier Trono
Journal:  Curr Protoc Hum Genet       Date:  2007-07

3.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

4.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

5.  A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Authors:  Marianne K-H Kim; Jacqueline M Mason; Chi-Ming Li; Windy Berkofsky-Fessler; Le Jiang; Divaker Choubey; Paul E Grundy; Benjamin Tycko; Jonathan D Licht
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

6.  Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.

Authors:  Ji-Young Kim; Hae Jin Kee; Nak-Won Choe; Sung-Mi Kim; Gwang-Hyeon Eom; Hee Jo Baek; Hyun Kook; Hoon Kook; Sang-Beom Seo
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

7.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.

Authors:  Zejuan Li; Jun Lu; Miao Sun; Shuangli Mi; Hao Zhang; Roger T Luo; Ping Chen; Yungui Wang; Ming Yan; Zhijian Qian; Mary Beth Neilly; Jie Jin; Yanming Zhang; Stefan K Bohlander; Dong-Er Zhang; Richard A Larson; Michelle M Le Beau; Michael J Thirman; Todd R Golub; Janet D Rowley; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-01       Impact factor: 11.205

Review 8.  Epigenetic changes in cancer.

Authors:  Kirsten Grønbaek; Christoffer Hother; Peter A Jones
Journal:  APMIS       Date:  2007-10       Impact factor: 3.205

9.  Characterization of MYC translocations in multiple myeloma cell lines.

Authors:  Amel Dib; Ana Gabrea; Oleg K Glebov; P Leif Bergsagel; W Michael Kuehl
Journal:  J Natl Cancer Inst Monogr       Date:  2008

10.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Marco Ladetto; Michael Kuehl; Tiziana Palumbo; Daniela Drandi; Cristian Taccioli; Nicola Zanesi; Hansjuerg Alder; John P Hagan; Reinhold Munker; Stefano Volinia; Mario Boccadoro; Ramiro Garzon; Antonio Palumbo; Rami I Aqeilan; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

View more
  36 in total

Review 1.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

Review 2.  Gene Expression Profiles in Myeloma: Ready for the Real World?

Authors:  Raphael Szalat; Herve Avet-Loiseau; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

Review 3.  Oxidative stress response and Nrf2 signaling in aging.

Authors:  Hongqiao Zhang; Kelvin J A Davies; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2015-06-09       Impact factor: 7.376

Review 4.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

Review 5.  Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.

Authors:  Chen Shen; Christopher R Vakoc
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

Review 6.  Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Authors:  Faiz Anwer; Kevin Mathew Gee; Ahmad Iftikhar; Mirza Baig; Atlantis Dawn Russ; Sabina Saeed; Muhammad Abu Zar; Faryal Razzaq; Jennifer Carew; Steffan Nawrocki; Hussam Al-Kateb; Nadia Nunes Cavalcante Parr; Ali McBride; Jason Valent; Christy Samaras
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-25

7.  The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Authors:  Simon Walz; Juliane S Stickel; Daniel Johannes Kowalewski; Heiko Schuster; Katja Weisel; Linus Backert; Stefan Kahn; Annika Nelde; Tatjana Stroh; Martin Handel; Oliver Kohlbacher; Lothar Kanz; Helmut Rainer Salih; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Blood       Date:  2015-07-02       Impact factor: 22.113

8.  UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.

Authors:  Teresa Ezponda; Daphné Dupéré-Richer; Christine M Will; Eliza C Small; Nobish Varghese; Tej Patel; Behnam Nabet; Relja Popovic; Jon Oyer; Marinka Bulic; Yupeng Zheng; Xiaoxiao Huang; Mrinal Y Shah; Sayantan Maji; Alberto Riva; Manuela Occhionorelli; Giovanni Tonon; Neil Kelleher; Jonathan Keats; Jonathan D Licht
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

Review 9.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

10.  MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.

Authors:  Z-X Yan; L-L Wu; K Xue; Q-L Zhang; Y Guo; M Romero; C Leboeuf; A Janin; S-J Chen; L Wang; W-L Zhao
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.